Atirmociclib

Relay Therapeutics plans to initiate ReDiscover-2, a Phase 3 trial evaluating RLY-2608 plus fulvestrant in PI3Kα-mutated, HR+/HER2- advanced breast cancer patients, with enrollment target of 540 patients.

Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.

Longer-term follow-up of the OlympiA trial confirms the benefit of adjuvant olaparib in BRCA-positive, HER2-negative breast cancer, reinforcing its role in improving survival outcomes.

Relay Therapeutics is laying off approximately 10% of its workforce, affecting about 30 employees, as part of a streamlining effort to enhance research efficiency.

Relay Therapeutics' RLY-2608, combined with fulvestrant, demonstrated a median progression-free survival of 9.2 months in pre-treated patients.